| Literature DB >> 29130348 |
Rossella De Marco1, Luca Gentilucci1.
Abstract
Recently, a new family of opioid peptides containing tryptophan came to the spotlight for the absence of the fundamental protonable tyramine 'message' pharmacophore. Structure-activity relationship investigations led to diverse compounds, characterized by different selectivity profiles and agonist or antagonist effects. Substitution at the indole of Trp clearly impacted peripheral/central antinociceptivity. These peculiarities prompted to gather all the compounds in a new class, and to coin the definition 'Tryptophan-Containing Non-Cationizable Opioid Peptides', in short 'TryCoNCOPs'. Molecular docking analysis suggested that the TryCoNCOPs can still interact with the receptors in an agonist-like fashion. However, most TryCoNCOPs showed significant differences between the in vitro and in vivo activities, suggesting that opioid activity may be elicited also via alternative mechanisms.Entities:
Keywords: CJ-15,208; agonism; antagonism; antinociception; bioavailability; drug abuse; endomorphin; molecular docking; opioid peptides; tryptophan
Mesh:
Substances:
Year: 2017 PMID: 29130348 DOI: 10.4155/fmc-2017-0104
Source DB: PubMed Journal: Future Med Chem ISSN: 1756-8919 Impact factor: 3.808